Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
Holding HALO?
Track your performance easily
HALO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$33.15 - $65.53
Previous Close$47.79
Volume3.21M
Average Volume (3M)1.68M
Market Cap
$6.08B
Enterprise Value$6.92B
Total Cash (Recent Filing)$666.31M
Total Debt (Recent Filing)$1.50B
Price to Earnings (P/E)15.8
Beta1.20
Next Earnings
Feb 25, 2025EPS Estimate
$1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.02
Shares Outstanding127,227,000
10 Day Avg. Volume2,754,873
30 Day Avg. Volume1,678,755
Standard Deviation0.13
R-Squared0.27
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)12.85
Price to Sales (P/S)6.02
Price to Cash Flow (P/CF)12.40
P/FCF Ratio12.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.30
Enterprise Value/Gross Profit10.86
Enterprise Value/Ebitda11.99
Forecast
1Y Price Target
$72.38Price Target Upside51.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Halozyme News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHalozyme is well-positioned for future growth with royalty streams stemming from the existing pipeline of ENHANZE-coformulated products.
Growth ProspectsConfidence remains in Halozyme's ability to achieve significant growth in royalty revenue and adjusted EBITDA, with targets of over $1 billion by 2027.
Market OpportunityThe ENHANZE platform enables under-the-skin (subcutaneous) administration of historically IV-administered drugs, significantly ameliorating convenience.
Bears Say
Acquisition RisksEvotec's board of directors does not appear to be open to the proposal and has hired an investment bank to prepare a defense to Halozyme's takeover bid.
Patent IssuesThe European Patent Office has decided to revoke another of JNJ’s co-formulation patents for Darzalex Faspro, highlighting a longer-term risk to HALO’s European Faspro royalties.
Royalty DeclineVyvgart royalties would now step down at the expiry of Enhanze patent in 2027 or 29, which means two important products could step down in the same year.
---
Ownership Overview
1.01% Insiders
31.21% Mutual Funds
25.98% Other Institutional Investors
13.45% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HALO FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was $33.15 and its highest was $65.53 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Currently, no data Available
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is Feb 25, 2025 which is in 91 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on Oct 31, 2024. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $0.958 by $0.312.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is $1.17.
How many shares outstanding does Halozyme Therapeutics have?
Halozyme Therapeutics has 127,227,000 shares outstanding.
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of $1.27 in its last earnings report, beating expectations of $0.958. Following the earnings report the stock price went up 13.012%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Among the largest hedge funds holding Halozyme Therapeutics’s share is Fisher Asset Management LLC. It holds Halozyme Therapeutics’s shares valued at 19M.
---
Halozyme Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$72.38 (51.45% Upside)
$72.38 (51.45% Upside)
Blogger Sentiment
Bullish
HALO Sentiment 92%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 32.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 8.0%
Last 30 Days ▲ 8.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.35%
12-Months-Change
Fundamentals
Return on Equity
111.83%
Trailing 12-Months
Asset Growth
11.91%
Trailing 12-Months
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
---
HALO Company Deck
---
HALO Earnings Call
Q3 2024
0:00 / 0:00
---
HALO Revenue Breakdown
54.01% Royalties
36.28% Product sales
9.71% Revenues under collaborative agreements
---
HALO Stock 12 Month Forecast
Average Price Target
$72.38
▲(51.45% Upside)
Technical Analysis
Best Analysts Covering HALO
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+16.10%
reiterated a buy rating 2 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +16.10% per trade.
---